Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus

Type 1 Diabetes Clinical Trial

— OPERA  

Official title:

A Randomized, Open-label, Pilot Study Evaluating the Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05413005
• Other study ID #: CT.004.1.1.OPERA
• Status: Active, not recruiting
• Phase: Early Phase 1
• Start date: September 5, 2022
• Est. completion date: June 1, 2025

Study information

• Verified date: January 2024
• Source: Abu Dhabi Stem Cells Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

OPERA Study is a randomized, open-label, prospective, pilot, and a monocentric clinical trial involving outpatients within Abu Dhabi Stem Cells Center (ADSCC) with a confirmed diagnosis of type 1 diabetes mellitus (T1DM). The patients will be randomly allocated (1:1) in a parallel assignment involving two groups of participants: Group A (Regular-intensity arm): Extracorporeal Photopheresis (ECP) on a regular-intensity regimen described in the Protocol as add-on T1DM standard of care, or Group B (Accelerated-intensity arm): ECP on an accelerated regimen plus T1DM standard of care.

Description:

The standard of care is defined as per the "DOH Standards for diagnosis, management and data reporting for diabetes" in combination with the DOH recommended NICE (UK National Institute for Health and Care Excellence) guidelines "Type 1 diabetes in adults: diagnosis and management (NG17)". OPERA Study will be fully conducted in ADSCC, including the patient assessment and inclusion, randomization, ECP procedures, and follow-up consultations, according to this Protocol and GCP principles. All patients will receive T1DM standard of care, plus additional ECP protocols on two regimens of investigational interventions. The primary objective is the safety assessment of ECP, to be assessed by the tolerability to the ECP procedures, incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) assessed by the CTCAE v5.0, and the WHO-UMC causality assessment system. The other primary objective is the preliminary efficacy assessment of the ECP as an add-on treatment to the standard of care for T1DM patients, assessed by the exogenous insulin use, HbA1c levels, C-peptide levels, and clinically important hypoglycemic episodes. The secondary objective is the assessment of the immune response profile in T1DM patients receiving standard of care and additional ECP procedures. The trial is approved by the institutional ADSCC Research Ethics Committee (REC) and written informed consent will be obtained from all patients. OPERA Study will be conducted following the principles of the Declaration of Helsinki and ICH-GCP guidelines.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 10
• Est. completion date: June 1, 2025
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

• Inclusion Criteria
• Confirmed and documented diagnosis of T1DM. Patients must have:
• A documented history of T1DM within the first 3 years of onset.
• Should be on a multiple dose injection (MDI) therapy.
• C-Peptide levels of ? 0.7 ng/mL.
• HbA1C = 6.5% to = 10%.
• Evidence of pancreatic autoimmunity, if available (positive anti-glutamic acid decarboxylase [GAD]; Islet antigen 2 [anti-IA2]; and/or zinc transporter 8 [ZnT8] antibodies).
• Male or female aged = 18 to = 50 years.
• Weight > 40 kg.
• Hematocrit = 32%.
• Platelet count = 100 x10^9/L (with or without transfusion support).
• Willingness to participate in all OPERA Study tests, visits, and ECP procedures, as outlined in the informed consent.
• Willingness to use at least one reliable method of birth control (e.g. abstinence, oral contraceptives, intrauterine devices, barrier method with spermicide, or surgical sterilization) throughout the study for all men and women of childbearing potential.
• The patient agrees to participate in the trial, and signs the OPERA Study informed consent form.
• Exclusion Criteria
• Pediatric aged < 18 or ? 50 years.
• Clinical diagnosis of type 2 diabetes mellitus (T2DM).
• Inability to tolerate fluid changes associated with ECP (e.g. inadequate renal, hepatic, pulmonary and cardiac function leading to enable patient to tolerate extracorporeal volume shifts associated with ECP).
• Hypersensitivity or allergy to citrate products.
• Hypersensitivity or allergy to psoralen compounds such as Methoxsalen (8-Methoxypsoralen, 8-MOP).
• Aphakia (8-MOP is contraindicated because of the significantly increased risk of retinal damage due to the absence of lenses).
• Presence of comorbidities that may result in photosensitivity (systemic lupus erythematosus, porphyries, albinism, etc.).
• Suspected or diagnosed Diabetic Ketoacidosis (DKA) at the moment of the screening visit.
• Uncontrolled infection requiring treatment at study entry.
• Laboratory evidence of any of the following:
• White Blood Cell (WBC) count < 3.00 x10^9/L.
• Serum transaminase levels > x2 upper normal limit (UNL).
• Hematocrit < 32%.
• Platelet count < 100 x10^9/L (with or without transfusion support).
• Diagnostic of Hepatitis B Virus (HBV) infection.
• Diagnostic of Human Immunodeficiency Virus (HIV) infection or Acquired Immunodeficiency Syndrome (AIDS).
• Pregnant or lactating women.
• Have participated in other clinical trial in the past 3 months.
• Organ transplants in the past 3 months.
• Current diagnosis of cancer.
• Inability to comply with all OPERA Study tests, visits, and procedures (including ECP).
• Inability to provide informed consent.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Combination Product:
• ECP regular-intensity arm
Weeks 1-8: Once every 2 weeks: weeks 1, 3, 5, 7 (cryo-ECP bags infused twice-a-week) Weeks 9-16: Once per month: weeks 9, 13 (cryo-ECP bags infused once-a-week) Weeks 17-24: One: week 17 (cryo-ECP bags infused every two weeks)
• ECP accelerated-intensity arm
Weeks 1-8: Once every week: weeks 1- 7 (cryo-ECP bags infused twice-a-week) Weeks 9-16: Cryo-ECP bags infused once-a-week Weeks 17-24: Cryo-ECP bags infused every two weeks

Biological:
• T1DM standard of care
The standard of care is defined as per the "DOH Standards for diagnosis, management and data reporting for diabetes" in combination with the DOH recommended NICE guidelines "Type 1 diabetes in adults: diagnosis and management (NG17)"

Locations

Country	Name	City	State
United Arab Emirates	Abu Dhabi Stem Cells Center	Abu Dhabi

Sponsors (1)

Lead Sponsor	Collaborator
Abu Dhabi Stem Cells Center

Country where clinical trial is conducted

United Arab Emirates, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tolerability to ECP procedures	Rate of tolerability of the ECP will be assessed by the number of ECP discontinuation due to adverse events (AE), or withdrawal of participants of the Study due to serious adverse events (SAEs)	Weeks 0 - 24
Primary	Incidence of adverse events (AEs)	Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs): Proportion of participants with AEs as assessed by CTCAE v5.0	Weeks 0 - 24
Primary	Exogenous insulin use	Rate of modification in exogenous insulin requirements compared with baseline. Marker for efficacy of treatment: reducing insulin dose	Baseline, months 3, 6, and 12
Primary	HbA1c levels	Rate of modification in HbA1c levels compared with baseline. Marker for efficacy of treatment: decreasing for a target HbA1c level of 48 mmol/mol [6.5%]	Baseline, months 3, 6, and 12
Primary	C-peptide levels	Rate of modification in C-Peptide levels compared with baseline. Marker for efficacy of treatment: increasing C-Peptide levels of = 0.7 ng/mL	Baseline, months 3, 6, and 12
Primary	Clinically important hypoglycemic episodes	Frequency of clinically important hypoglycemic episodes (described in Protocol).; Marker for efficacy of treatment: requiring decrease of insulin dose)	Baseline - Month 12
Secondary	Immune response profile (cellular)	CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD20, CD25, CD27, CD28, CD38, CD45, CD45RA, CD45RO, CD56, CD57, CD66b, CD123, CD127, CD161, CD294, CCR4, CCR6, CCR7, CXCR3, CXCR5, will be assessed for identification of immune cells and subsets analyses	Baseline, months 3, 6, and 12
Secondary	Serum IgG levels	Serum IgG concentration will be assessed for characterization of the humoral response profile	Baseline, months 3, 6, and 12
Secondary	Serum IgA levels	Serum IgA concentration will be assessed for characterization of the humoral response profile	Baseline, months 3, 6, and 12
Secondary	Serum IgM levels	Serum IgM concentration will be assessed for characterization of the humoral response profile	Baseline, months 3, 6, and 12